The monoclonal antibody studied was hIgG1-CD4 or Campath-9 [30], which is a humanized IgG1-type antibody against CD4 antigen and which has been used in human clinical trials for the treatment of rheumatoid arthritis and psoriasis. Here, CD4 is linked to psoriasis.